过去 70 年来，人们对预防化疗相关的心血管并发症进行了广泛的研究。然而，心脏肿瘤学研究的现状提出的问题多于答案。实验研究经常提供难以比较的数据，有时甚至是矛盾的。将实验结果转化为临床实践的一个显着限制是依赖于仅向实验动物施用一种化疗药物的模型，尽管在实际临床环境中普遍使用多种药物癌症治疗。本文旨在讨论我们在建立由两种化疗药物阿霉素（阿霉素）和环磷酰胺（AC 化疗模式）诱导的实验性大鼠心肌病模型方面的经验 - Avagimyan A. 等人的模型，以及随后的模型根据我们的个人档案审查形态变化。版权所有 © 2024。由 Elsevier Inc. 出版。

Over the past 70 years, there has been extensive research focused on preventing chemotherapy-related cardiovascular complications. However, the current state of cardio-oncology research has raised more questions than answers. Experimental studies often present data that are difficult to compare and, at times, contradictory. One notable limitation in translating experimental findings to clinical practice is the reliance on models that administer only one chemotherapeutic drug to experimental animals, despite the common use of multidrug cancer treatments in real clinical settings. This article aims to discuss our own experience in modeling an experimental rat model of cardiomyopathy induced by the administration of two chemotherapeutic drugs, doxorubicin (adriamycin) and cyclophosphamide (AC mode of chemotherapy) - Avagimyan A., et al model, along with a subsequent review of morphological changes based on our personal archive.Copyright © 2024. Published by Elsevier Inc.